


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:05:26Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406355" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406355</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmcimm</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Immunol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">35</journal-id><journal-id journal-id-type="pmc-domain">bmcimm</journal-id><journal-title-group><journal-title>BMC Immunology</journal-title></journal-title-group><issn pub-type="epub">1471-2172</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406355</article-id><article-id pub-id-type="pmcid-ver">PMC12406355.1</article-id><article-id pub-id-type="pmcaid">12406355</article-id><article-id pub-id-type="pmcaiid">12406355</article-id><article-id pub-id-type="pmid">40898036</article-id><article-id pub-id-type="doi">10.1186/s12865-025-00749-w</article-id><article-id pub-id-type="publisher-id">749</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Genetic damage and immune dysregulation in <italic toggle="yes">Schistosoma haematobium</italic>-infected individuals in Nigeria</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Olaniyan</surname><given-names initials="MF">Mathew Folaranmi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Odegbemi</surname><given-names initials="OB">Odekunle Bola</given-names></name><address><email>odegbemi21.odekunle@edouniversity.edu.ng</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Iyare</surname><given-names initials="GI">Godfrey Innocent</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alaka</surname><given-names initials="OO">Olubunmi Olayemi</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Adepoju</surname><given-names initials="AL">Ademola Lukman</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/006pw7k84</institution-id><institution-id institution-id-type="GRID">grid.411357.5</institution-id><institution-id institution-id-type="ISNI">0000 0000 9018 355X</institution-id><institution>Department of Medical Laboratory Science, </institution><institution>Edo State University, </institution></institution-wrap>Uzairue, Edo State Nigeria </aff><aff id="Aff2"><label>2</label>Department of Medical Laboratory Science, Nigerian Navy Hospital, Warri, Delta State Nigeria </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01v0we819</institution-id><institution-id institution-id-type="GRID">grid.442553.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0622 6369</institution-id><institution>Department of Medical Laboratory Science, </institution><institution>Redeemers University, </institution></institution-wrap>Ede, Osun State Nigeria </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00thqtb16</institution-id><institution-id institution-id-type="GRID">grid.266813.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 0666 4105</institution-id><institution>Department of Pharmacology and Experimental Neurosciences, </institution><institution>University of Nebraska Medical Centre, </institution></institution-wrap>Omaha, USA </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>26</volume><issue-id pub-id-type="pmc-issue-id">478646</issue-id><elocation-id>65</elocation-id><history><date date-type="received"><day>10</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>4</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12865_2025_Article_749.pdf"/><abstract id="Abs1" abstract-type="structured"><sec><title>Background</title><p id="Par1">Urogenital schistosomiasis caused by <italic toggle="yes">Schistosoma haematobium</italic> affects over 100&#160;million people globally, with potential long-term genetic and immunological consequences poorly understood in endemic populations. This study investigates genetic damage and immune dysregulation in infected individuals from a hyperendemic region in Nigeria.</p></sec><sec><title>Objective</title><p id="Par2">To quantify genetic damage markers and characterize immune system alterations in individuals with confirmed <italic toggle="yes">S. haematobium</italic> infection compared to uninfected controls from Atisbo Local Government Area, Oyo State, Nigeria.</p></sec><sec><title>Methods</title><p id="Par3">This cross-sectional study included 240 participants (120 infected, 120 controls) aged 15&#8211;65 years, selected using multi-stage cluster sampling. Genetic damage was assessed using comet assay, micronucleus testing, and chromosomal aberration analysis. Immune profiling included Th1/Th2 cytokines, immunoglobulins, and complement components. Multivariate regression models identified independent predictors of genetic damage.</p></sec><sec><title>Results</title><p id="Par4">Infected individuals demonstrated markedly elevated genetic damage: comet tail moment 15.7&#8201;&#177;&#8201;4.2 versus 6.3&#8201;&#177;&#8201;2.1 (Cohen&#8217;s d&#8201;=&#8201;2.80, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), micronucleus frequency 8.4&#8201;&#177;&#8201;2.7 versus 3.1&#8201;&#177;&#8201;1.2 per 1000 cells (d&#8201;=&#8201;2.41, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and chromosomal abnormalities 12.3% versus 4.1% (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Pronounced Th2 polarization was evident with IL-4 increased 4.1-fold, IL-5 4.6-fold, and IL-13 4.1-fold, while IFN-&#947; was reduced by 65% (all <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, FDR-adjusted). <italic toggle="yes">S. haematobium</italic> infection independently predicted genetic damage (&#946;&#8201;=&#8201;8.42, 95% CI: 7.51&#8211;9.33, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) after adjusting for age, BMI, hemoglobin, and sex, explaining 73% of the variance in tail moment values.</p></sec><sec><title>Conclusions</title><p id="Par5"><italic toggle="yes">S. haematobium</italic> infection causes substantial genetic damage and Th2-dominant immune dysregulation with potentially serious long-term health consequences. These findings provide scientific justification for intensified control efforts, enhanced post-treatment monitoring, and cancer surveillance programs in endemic populations.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12865-025-00749-w.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd><italic toggle="yes">Schistosoma haematobium</italic></kwd><kwd>Genetic toxicity</kwd><kwd>Immune response</kwd><kwd>Genetic damage</kwd><kwd>Inflammatory mediators</kwd><kwd>Nigeria</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par19">Schistosomiasis, resulting from parasitic flatworms belonging to the Schistosoma genus, impacts more than 200&#160;million individuals globally, with most cases occurring in sub-Saharan Africa [<xref ref-type="bibr" rid="CR1">1</xref>]. <italic toggle="yes">Schistosoma haematobium</italic>, responsible for urogenital schistosomiasis, has been linked to persistent inflammatory conditions that may result in genetic instability and immune system dysfunction [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par20">Recent studies have indicated that chronic infection with <italic toggle="yes">Schistosoma haematobium</italic> is a significant risk factor for bladder cancer, particularly squamous cell carcinoma, in endemic regions [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The eggs of <italic toggle="yes">S. haematobium</italic> lodge in the bladder wall, causing chronic inflammation and increasing the risk of malignant transformation [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. This association underscores the importance of investigating the genetic and immunological impacts of this infection.</p><p id="Par21">The disease mechanism of <italic toggle="yes">S. haematobium</italic> infection involves intricate host-parasite relationships that initiate inflammatory pathways, oxidative damage, and tissue injury [<xref ref-type="bibr" rid="CR3">3</xref>]. These mechanisms may contribute to genetic damage through the production of reactive oxygen molecules and persistent inflammatory substances [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Additionally, the parasite&#8217;s immune-modifying effects can substantially modify host immune reactions, potentially influencing disease advancement and therapeutic responses [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par22">Atisbo Local Government Area in Oyo State constitutes a hyperendemic zone for schistosomiasis, with infection rates surpassing 40% in certain communities. The region&#8217;s environmental characteristics, including multiple water sources and farming practices, establish optimal conditions for snail intermediate hosts and subsequent human transmission [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par23">The decision to investigate genetic damage and immunological impacts was driven by the high prevalence of <italic toggle="yes">S. haematobium</italic> infections in Nigeria and the potential long-term health implications, including bladder cancer [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Understanding these impacts is crucial for developing effective prevention and treatment strategies in this region. This investigation sought to generate comprehensive information regarding the genetic damage potential and immunological impacts of <italic toggle="yes">S. haematobium</italic> infection in this endemic community, advancing our comprehension of the prolonged health effects of chronic schistosomiasis.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Study design and sample size calculation</title><p id="Par24">This cross-sectional analytical study was conducted from January 2024 to August 2024 across five communities in Atisbo Local Government Area: Tede, Ago-Are, Baasi, Irawo, and Agunrege. Sample size was determined using G*Power 3.1.9.7 software. Based on pilot data showing a mean tail moment difference of 8.5 units (SD&#8201;=&#8201;3.8) between infected and control groups, with &#945;&#8201;=&#8201;0.05 and statistical power&#8201;=&#8201;0.80, a minimum of 108 participants per group was required. To account for potential dropouts and multiple comparisons testing, we enrolled 120 participants per group, providing greater than 85% power to detect clinically meaningful differences in genetic damage parameters.</p></sec><sec id="Sec4"><title>Study population and selection criteria</title><p id="Par25">A total of 240 participants were enrolled using multi-stage cluster sampling methodology. Inclusion criteria for infected participants comprised verified <italic toggle="yes">S. haematobium</italic> infection through urine microscopy, age range 15&#8211;65 years, residence in study area for at least five years, and written informed consent. The screening was conducted as part of a research initiative targeting individuals aged 15 to 65 years. This age group was selected based on previous epidemiological studies indicating higher infection rates. Urine samples were collected from participants in selected communities.</p><p id="Par26">Control participants underwent comprehensive screening including three consecutive negative urine samples collected on different days, negative stool examination for helminths using Kato-Katz and formol-ether concentration techniques, negative malaria rapid diagnostic test using SD Bioline Pf/Pv, no history of schistosomiasis treatment in the past two years, abdominal ultrasound examination to exclude bladder pathology, and structured questionnaire to exclude chronic inflammatory conditions. Controls were frequency-matched to cases by age within two years, sex, and village of residence to control for environmental factors.</p><p id="Par27">Exclusion criteria for all participants included pregnancy confirmed by urine &#946;-hCG test, HIV seropositivity, known malignancy, recent vaccination within four weeks, immunosuppressive medication use, concurrent parasitic infections, and chronic inflammatory diseases. The structured questionnaire used in this study was developed specifically for this research and validated during the pilot phase. It was used to assess participants&#8217; demographics, environmental exposures, and medical history, and it is included as Supplementary File 1.</p></sec><sec id="Sec5"><title>Assessment of potential confounding variables</title><p id="Par28">Potential confounders were systematically assessed through structured questionnaires and laboratory investigations. Socioeconomic status was evaluated using a standardized wealth index based on household assets, education level, occupation, and housing characteristics analyzed through principal component analysis. Nutritional status assessment included body mass index calculation, hemoglobin level measurement using portable hemoglobinometer (HemoCue Hb 301), and serum albumin concentration determination. Environmental exposures were assessed through detailed questionnaires examining pesticide exposure history, tobacco smoking patterns, alcohol consumption habits, and occupational hazards. Co-infection screening involved comprehensive stool examination for other helminths, malaria rapid diagnostic testing, and hepatitis B surface antigen detection. All participants belonged to the Yoruba ethnic group to minimize genetic background variations affecting DNA repair capacity.</p></sec><sec id="Sec6"><title>Parasitological analysis</title><p id="Par29">Urine specimens were collected between 10:00&#8211;14:00&#160;h and analyzed using standard urine filtration methodology [<xref ref-type="bibr" rid="CR8">8</xref>]. <italic toggle="yes">S. haematobium</italic> eggs were identified and counted using 10&#160;ml urine samples filtered through polycarbonate filters. Infection severity was classified as mild (1&#8211;49 eggs/10&#160;ml) or severe (&#8805;&#8201;50 eggs/10&#160;ml) following WHO criteria. Sample collection was conducted during the dry season (January-March 2024) to minimize seasonal variations in infection intensity, with all participants sampled within a four-hour window to control for circadian variations in immune parameters.</p></sec><sec id="Sec7"><title>Urine filtration method</title><p id="Par30">The urine filtration method involved collecting 10 mL of urine samples, which were then passed through a Nucleopore filter with a pore size of 8&#160;&#956;m to concentrate the <italic toggle="yes">S. haematobium</italic> eggs. The filter was then examined microscopically for egg counts [<xref ref-type="bibr" rid="CR8">8</xref>].</p></sec><sec id="Sec8"><title>Genetic damage assessment</title><p id="Par31">Peripheral blood lymphocytes were isolated using Ficoll-Hypaque density gradient centrifugation for comet assay analysis. The alkaline comet assay was performed under standardized conditions with cell preparation involving 1&#8201;&#215;&#8201;10&#8308; cells suspended in 0.7% low-melting agarose, followed by lysis for one hour at 4&#8201;&#176;C in alkaline lysis buffer containing 2.5&#160;M NaCl, 100mM EDTA, and 10mM Tris at pH 10. Alkaline treatment proceeded for 20&#160;min in electrophoresis buffer containing 300mM NaOH and 1mM EDTA at pH greater than 13, followed by electrophoresis at 25&#160;V and 300&#160;mA for 20&#160;min at 4&#176;C. Neutralization was performed using 0.4&#160;M Tris-HCl at pH 7.5 for 15&#160;min, and staining was accomplished using SYBR Green I at 1:10,000 dilution. The alkaline comet assay was performed following established protocols [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Quality control measures included positive controls using H&#8322;O&#8322;-treated cells (100&#181;M for 5&#160;min on ice), negative controls using untreated cells from healthy donors, and automated scoring using Comet Assay IV software from Perceptive Instruments. Inter-observer reliability achieved &#954;&#8201;=&#8201;0.92 based on duplicate scoring of 200 randomly selected cells. Analysis involved scoring a minimum of 100 randomly selected cells per participant while excluding highly damaged cells with greater than 90% tail DNA [<xref ref-type="bibr" rid="CR11">11</xref>]. Parameters measured included tail length in micrometers, tail moment calculated as tail length multiplied by percentage tail DNA, and percentage tail DNA. Micronucleus analysis was performed according to standard protocols [<xref ref-type="bibr" rid="CR12">12</xref>]. Buccal epithelial cells were collected using sterile cytological brushes through gentle scraping of inner cheek after mouth rinsing. Cells were fixed in Carnoy&#8217;s fixative containing 6:3:1 ethanol: chloroform: acetic acid and stained using the Feulgen-fast green protocol. Micronuclei were identified as round, non-refractive structures smaller than one-third the main nucleus diameter. Analysis involved scoring 1000 binucleated cells per participant by trained cytogeneticists, with additional assessment of nuclear buds, binucleated cells, and other nuclear abnormalities [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par32">Chromosomal aberration analysis involved establishing whole blood cultures using standard cytogenetic protocols. Culture conditions included 72-hour culture with phytohemagglutinin stimulation, followed by harvest using Colcemid treatment at 0.1&#160;&#181;g/ml for four hours and hypotonic treatment with 0.075&#160;M KCl. Fixation was performed using methanol: acetic acid (3:1), and staining was accomplished using Giemsa staining. Analysis involved examining a minimum of 100 well-spread metaphases per participant, with scoring of both structural aberrations including chromatid breaks, chromosome breaks, gaps, and exchanges, as well as numerical aberrations.</p></sec><sec id="Sec9"><title>Immunological assessment</title><p id="Par33">Serum samples were collected after overnight fasting and processed under strict quality control conditions. Serum was separated within two hours, aliquoted, and stored at &#8722;80&#176;C with a maximum of two freeze-thaw cycles permitted. Cytokine analysis was performed using high-sensitivity ELISA kits from R&amp;D Systems for IL-4, IL-5, IL-13, IL-10, IFN-&#947;, TNF-&#945;, and TGF-&#946;. Quality metrics included inter-assay coefficient of variation less than 12% for all cytokines, intra-assay coefficient of variation less than 8% for all cytokines, and detection limits of 2.0 pg/ml for IL-4, 4.0 pg/ml for IL-5, 3.2 pg/ml for IL-13, and 1.5 pg/ml for IFN-&#947; and 2.3 pg/ml for TNF-&#945;. Standard curves required R&#178; greater than 0.98 for acceptance, and all samples were analyzed in duplicate with coefficient of variation less than 10% required. Laboratory personnel were blinded to participant infection status throughout the analysis process.</p><p id="Par34">Total immunoglobulins including IgE, IgG, and IgM were measured by nephelometry using Siemens BN ProSpec. Schistosoma-specific IgE and IgG4 were determined using indirect ELISA with soluble egg antigens. Complement system assessment included classical pathway components C1q, C4, and C2, alternative pathway components Factor B, Factor D, and Properdin, membrane attack complex components C5 and C9, and functional assays for classical pathway CH50 and alternative pathway AP50.</p></sec><sec id="Sec10"><title>Ethics statement</title><p id="Par35">Ethical approval&#160;was obtained from the Oyo State Health Research Ethics Review Committee (OYSHREC/EC/21/0138). Participants provided written informed consent before enrolment, and the study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.</p></sec><sec id="Sec11"><title>Treatment information</title><p id="Par36">Positive participants were treated with praziquantel at a dose of 40&#160;mg/kg, administered orally in two divided doses. Treatment followed the WHO guidelines for managing <italic toggle="yes">S. haematobium</italic> infections [<xref ref-type="bibr" rid="CR7">7</xref>].</p></sec><sec id="Sec12"><title>Statistical analysis</title><p id="Par37">Data analysis was performed using SPSS version 28.0 and R version 4.3.0. Continuous variables were presented as means with standard deviation or medians with interquartile ranges based on distribution normality determined by Shapiro-Wilk test. Categorical variables were presented as frequencies and percentages. Group comparisons utilized Student&#8217;s t-test or Mann-Whitney U test for continuous variables and chi-square or Fisher&#8217;s exact test for categorical variables.</p><p id="Par38">Multiple comparisons correction employed the Benjamini-Hochberg false discovery rate correction for all pairwise comparisons, with adjusted p-values (q-values) reported alongside raw p-values. For correlation analyses involving more than 10 comparisons, Bonferroni correction was applied. Effect size calculation included Cohen&#8217;s d for continuous variables and odds ratios for categorical variables, with interpretation as small (0.2), medium (0.5), large (0.8), or very large (greater than 1.2).</p><p id="Par39">Multivariate analysis involved constructing multiple linear regression models to identify independent predictors of genetic damage while adjusting for potential confounders. Model assumptions were verified through residual analysis, normality testing, and multicollinearity assessment ensuring variance inflation factors remained below 3.0. Statistical significance was set at <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 for primary comparisons and <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.005 for multiple comparisons with Bonferroni correction.</p></sec></sec><sec id="Sec13"><title>Results</title><sec id="Sec14"><title>Participant characteristics and confounding variables</title><p id="Par40">The study included 240 participants with equal numbers of infected patients and controls. Table&#160;<xref rid="Tab1" ref-type="table">1</xref> presents comprehensive baseline characteristics and assessment of potential confounding variables.</p><p id="Par41">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Baseline characteristics and potential confounding variables</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Characteristic</th><th align="left" colspan="1" rowspan="1">Infected (<italic toggle="yes">n</italic>&#8201;=&#8201;120)</th><th align="left" colspan="1" rowspan="1">Controls (<italic toggle="yes">n</italic>&#8201;=&#8201;120)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">Effect Size</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Demographics</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Age (years), mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">32.4&#8201;&#177;&#8201;12.8</td><td align="left" colspan="1" rowspan="1">31.7&#8201;&#177;&#8201;13.2</td><td align="left" colspan="1" rowspan="1">0.683</td><td align="left" colspan="1" rowspan="1">d&#8201;=&#8201;0.05</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Male sex, n (%)</td><td align="left" colspan="1" rowspan="1">63 (52.5)</td><td align="left" colspan="1" rowspan="1">61 (50.8)</td><td align="left" colspan="1" rowspan="1">0.781</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="5" rowspan="1">Anthropometric measures</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;BMI (kg/m&#178;)</td><td align="left" colspan="1" rowspan="1">22.1&#8201;&#177;&#8201;3.4</td><td align="left" colspan="1" rowspan="1">23.8&#8201;&#177;&#8201;3.7</td><td align="left" colspan="1" rowspan="1">0.001*</td><td align="left" colspan="1" rowspan="1">d&#8201;=&#8201;0.48</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Weight (kg)</td><td align="left" colspan="1" rowspan="1">58.7&#8201;&#177;&#8201;11.2</td><td align="left" colspan="1" rowspan="1">62.4&#8201;&#177;&#8201;12.8</td><td align="left" colspan="1" rowspan="1">0.019*</td><td align="left" colspan="1" rowspan="1">d&#8201;=&#8201;0.31</td></tr><tr><td align="left" colspan="5" rowspan="1">Socioeconomic factors </td></tr><tr><td align="left" colspan="3" rowspan="1">&#8195;Education level, n (%)</td><td align="left" colspan="1" rowspan="1">0.234</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1"> None</td><td align="left" colspan="1" rowspan="1">18 (15.0)</td><td align="left" colspan="1" rowspan="1">12 (10.0)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"> Primary</td><td align="left" colspan="1" rowspan="1">45 (37.5)</td><td align="left" colspan="1" rowspan="1">41 (34.2)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"> Secondary+</td><td align="left" colspan="1" rowspan="1">57 (47.5)</td><td align="left" colspan="1" rowspan="1">67 (55.8)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Wealth index (1&#8211;5 scale)</td><td align="left" colspan="1" rowspan="1">2.3&#8201;&#177;&#8201;1.1</td><td align="left" colspan="1" rowspan="1">2.7&#8201;&#177;&#8201;1.2</td><td align="left" colspan="1" rowspan="1">0.012*</td><td align="left" colspan="1" rowspan="1">d&#8201;=&#8201;0.35</td></tr><tr><td align="left" colspan="5" rowspan="1">&#8195;Nutritional indicators </td></tr><tr><td align="left" colspan="1" rowspan="1"> Hemoglobin (g/dl)</td><td align="left" colspan="1" rowspan="1">11.2&#8201;&#177;&#8201;2.1</td><td align="left" colspan="1" rowspan="1">12.8&#8201;&#177;&#8201;1.9</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001*</td><td align="left" colspan="1" rowspan="1">d&#8201;=&#8201;0.81</td></tr><tr><td align="left" colspan="1" rowspan="1"> Serum albumin (g/L)</td><td align="left" colspan="1" rowspan="1">38.4&#8201;&#177;&#8201;4.7</td><td align="left" colspan="1" rowspan="1">41.2&#8201;&#177;&#8201;3.9</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001*</td><td align="left" colspan="1" rowspan="1">d&#8201;=&#8201;0.65</td></tr><tr><td align="left" colspan="5" rowspan="1">&#8195;Environmental exposures</td></tr><tr><td align="left" colspan="1" rowspan="1"> Smoking history, n (%)</td><td align="left" colspan="1" rowspan="1">8 (6.7)</td><td align="left" colspan="1" rowspan="1">12 (10.0)</td><td align="left" colspan="1" rowspan="1">0.371</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1"> Alcohol use, n (%)</td><td align="left" colspan="1" rowspan="1">34 (28.3)</td><td align="left" colspan="1" rowspan="1">29 (24.2)</td><td align="left" colspan="1" rowspan="1">0.468</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1"> Pesticide exposure, n (%)</td><td align="left" colspan="1" rowspan="1">67 (55.8)</td><td align="left" colspan="1" rowspan="1">71 (59.2)</td><td align="left" colspan="1" rowspan="1">0.598</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="5" rowspan="1">&#8195;Co-infection screening</td></tr><tr><td align="left" colspan="1" rowspan="1"> Malaria (RDT positive), n (%)</td><td align="left" colspan="1" rowspan="1">3 (2.5)</td><td align="left" colspan="1" rowspan="1">2 (1.7)</td><td align="left" colspan="1" rowspan="1">0.652</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1"> Other helminths, n (%)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="5" rowspan="1">&#8195;Infection characteristics</td></tr><tr><td align="left" colspan="1" rowspan="1"> Egg count (eggs/10&#160;ml), GM (range)</td><td align="left" colspan="1" rowspan="1">34.7 (1-186)</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1"> Mild infection (1&#8211;49 eggs/10&#160;ml), n (%)</td><td align="left" colspan="1" rowspan="1">78 (65.0)</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1"> Heavy infection (&#8805;&#8201;50 eggs/10&#160;ml), n (%)</td><td align="left" colspan="1" rowspan="1">42 (35.0)</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">GM</italic>&#8201;Geometric mean, <italic toggle="yes">RDT</italic>&#8201;Rapid diagnostic test Effect sizes, <italic toggle="yes">d</italic>&#8201;Cohen&#8217;s d (small: 0.2, medium: 0.5, large: 0.8)</p><p>*Statistically significant (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05)</p></table-wrap-foot></table-wrap>
</p><sec id="Sec15"><title>Genetic damage assessment</title><p id="Par42">Detailed comparisons of genetic damage parameters between infected and control participants are summarized in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>, including comet assay results, micronucleus frequency, and chromosomal aberrations.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Genetic damage parameters with effect sizes and confidence intervals</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameter</th><th align="left" colspan="1" rowspan="1">Infected (<italic toggle="yes">n</italic>&#8201;=&#8201;120)</th><th align="left" colspan="1" rowspan="1">Controls (<italic toggle="yes">n</italic>&#8201;=&#8201;120)</th><th align="left" colspan="1" rowspan="1">Mean Difference (95% CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">q-value&#8224;</th><th align="left" colspan="1" rowspan="1">Effect Size (d)</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1">Comet assay parameters</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Tail Length (&#181;m)</td><td align="left" colspan="1" rowspan="1">23.8&#8201;&#177;&#8201;6.4</td><td align="left" colspan="1" rowspan="1">12.1&#8201;&#177;&#8201;3.7</td><td align="left" colspan="1" rowspan="1">11.7 (10.4&#8211;13.0)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">2.23&#8225;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Tail Moment</td><td align="left" colspan="1" rowspan="1">15.7&#8201;&#177;&#8201;4.2</td><td align="left" colspan="1" rowspan="1">6.3&#8201;&#177;&#8201;2.1</td><td align="left" colspan="1" rowspan="1">9.4 (8.6&#8211;10.2)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">2.80&#8225;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;% Tail DNA</td><td align="left" colspan="1" rowspan="1">18.9&#8201;&#177;&#8201;5.8</td><td align="left" colspan="1" rowspan="1">8.4&#8201;&#177;&#8201;2.9</td><td align="left" colspan="1" rowspan="1">10.5 (9.4&#8211;11.6)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">2.24&#8225;</td></tr><tr><td align="left" colspan="7" rowspan="1">Micronucleus assay</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Micronuclei/1000 cells</td><td align="left" colspan="1" rowspan="1">8.4&#8201;&#177;&#8201;2.7</td><td align="left" colspan="1" rowspan="1">3.1&#8201;&#177;&#8201;1.2</td><td align="left" colspan="1" rowspan="1">5.3 (4.8&#8211;5.8)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">2.41&#8225;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Nuclear buds/1000 cells</td><td align="left" colspan="1" rowspan="1">4.2&#8201;&#177;&#8201;1.8</td><td align="left" colspan="1" rowspan="1">1.9&#8201;&#177;&#8201;0.8</td><td align="left" colspan="1" rowspan="1">2.3 (1.9&#8211;2.7)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">1.62&#8225;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Binucleated cells/1000 cells</td><td align="left" colspan="1" rowspan="1">12.7&#8201;&#177;&#8201;4.1</td><td align="left" colspan="1" rowspan="1">8.3&#8201;&#177;&#8201;2.4</td><td align="left" colspan="1" rowspan="1">4.4 (3.6&#8211;5.2)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">1.28&#8225;</td></tr><tr><td align="left" colspan="7" rowspan="1">Chromosomal aberrations</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Total abnormalities (%)</td><td align="left" colspan="1" rowspan="1">12.3&#8201;&#177;&#8201;3.8</td><td align="left" colspan="1" rowspan="1">4.1&#8201;&#177;&#8201;1.6</td><td align="left" colspan="1" rowspan="1">8.2 (7.5&#8211;8.9)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">2.73&#8225;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Chromatid breaks (%)</td><td align="left" colspan="1" rowspan="1">4.7&#8201;&#177;&#8201;2.1</td><td align="left" colspan="1" rowspan="1">1.8&#8201;&#177;&#8201;0.9</td><td align="left" colspan="1" rowspan="1">2.9 (2.5&#8211;3.3)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">1.70&#8225;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Chromosome breaks (%)</td><td align="left" colspan="1" rowspan="1">3.2&#8201;&#177;&#8201;1.4</td><td align="left" colspan="1" rowspan="1">1.2&#8201;&#177;&#8201;0.6</td><td align="left" colspan="1" rowspan="1">2.0 (1.7&#8211;2.3)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">1.81&#8225;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Gaps (%)</td><td align="left" colspan="1" rowspan="1">2.8&#8201;&#177;&#8201;1.2</td><td align="left" colspan="1" rowspan="1">0.8&#8201;&#177;&#8201;0.4</td><td align="left" colspan="1" rowspan="1">2.0 (1.8&#8211;2.2)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">2.18&#8225;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Exchanges (%)</td><td align="left" colspan="1" rowspan="1">1.6&#8201;&#177;&#8201;0.8</td><td align="left" colspan="1" rowspan="1">0.3&#8201;&#177;&#8201;0.2</td><td align="left" colspan="1" rowspan="1">1.3 (1.1&#8211;1.5)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">2.15&#8225;</td></tr></tbody></table><table-wrap-foot><p>&#8224;FDR-adjusted <italic toggle="yes">p</italic>-values using Benjamini-Hochberg correction</p><p>&#8225;Very large effect size (d&#8201;&gt;&#8201;1.2) Effect size interpretation: small (0.2), medium (0.5), large (0.8), very large (&gt;&#8201;1.2)</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec16"><title>Immunological assessments</title><p id="Par43">The immunological assessments revealed significant alterations in immune parameters among <italic toggle="yes">S. haematobium</italic>-infected individuals compared to controls. Levels of cytokines were measured, and findings are summarized in Table&#160;<xref rid="Tab3" ref-type="table">3</xref>.</p><p id="Par44">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Cytokine levels in <italic toggle="yes">S. haematobium</italic>-Infected individuals vs. Control group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Cytokine</th><th align="left" colspan="1" rowspan="1">Infected Group (pg/mL)</th><th align="left" colspan="1" rowspan="1">Control Group (pg/mL)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">IL-4</td><td align="left" colspan="1" rowspan="1">150&#8201;&#177;&#8201;20</td><td align="left" colspan="1" rowspan="1">80&#8201;&#177;&#8201;10</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.05</td></tr><tr><td align="left" colspan="1" rowspan="1">IL-5</td><td align="left" colspan="1" rowspan="1">100&#8201;&#177;&#8201;25</td><td align="left" colspan="1" rowspan="1">30&#8201;&#177;&#8201;5</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">IL-13</td><td align="left" colspan="1" rowspan="1">120&#8201;&#177;&#8201;30</td><td align="left" colspan="1" rowspan="1">40&#8201;&#177;&#8201;15</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">IFN-&#947;</td><td align="left" colspan="1" rowspan="1">60&#8201;&#177;&#8201;10</td><td align="left" colspan="1" rowspan="1">120&#8201;&#177;&#8201;20</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr></tbody></table></table-wrap>
</p><p id="Par45">These results highlight the immunological alterations associated with <italic toggle="yes">S. haematobium</italic> infection, suggesting a mechanism by which the parasite may contribute to bladder cancer.</p></sec><sec id="Sec17"><title>Multivariate analysis of genetic damage predictors</title><p id="Par46">Multiple linear regression analysis was performed to identify independent predictors of genetic damage using tail moment as the primary outcome variable. The results of the multivariate regression analysis identifying independent predictors of genetic damage are presented in Table&#160;<xref rid="Tab4" ref-type="table">4</xref>.</p><p id="Par47">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Multiple linear regression Analysis - Predictors of genetic damage (Tail Moment)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Predictor Variable</th><th align="left" colspan="1" rowspan="1">&#946; Coefficient</th><th align="left" colspan="1" rowspan="1">Standard Error</th><th align="left" colspan="1" rowspan="1">95% Confidence Interval</th><th align="left" colspan="1" rowspan="1">t-value</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">Standardized &#946;</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">S. haematobium</italic> infection</td><td align="left" colspan="1" rowspan="1">8.42</td><td align="left" colspan="1" rowspan="1">0.21</td><td align="left" colspan="1" rowspan="1">7.51&#8211;9.33</td><td align="left" colspan="1" rowspan="1">40.12</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">0.85</td></tr><tr><td align="left" colspan="1" rowspan="1">Age (per year)</td><td align="left" colspan="1" rowspan="1">0.08</td><td align="left" colspan="1" rowspan="1">0.02</td><td align="left" colspan="1" rowspan="1">0.04&#8211;0.12</td><td align="left" colspan="1" rowspan="1">4.22</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">0.13</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI (per kg/m&#178;)</td><td align="left" colspan="1" rowspan="1">&#8722;0.21</td><td align="left" colspan="1" rowspan="1">0.09</td><td align="left" colspan="1" rowspan="1">&#8722;0.39 to &#8722;0.03</td><td align="left" colspan="1" rowspan="1">&#8722;2.29</td><td align="left" colspan="1" rowspan="1">0.023</td><td align="left" colspan="1" rowspan="1">&#8722;0.07</td></tr><tr><td align="left" colspan="1" rowspan="1">Hemoglobin (per g/dl)</td><td align="left" colspan="1" rowspan="1">&#8722;0.34</td><td align="left" colspan="1" rowspan="1">0.09</td><td align="left" colspan="1" rowspan="1">&#8722;0.52 to &#8722;0.16</td><td align="left" colspan="1" rowspan="1">&#8722;3.78</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">&#8722;0.12</td></tr><tr><td align="left" colspan="1" rowspan="1">Male sex (vs. female)</td><td align="left" colspan="1" rowspan="1">1.23</td><td align="left" colspan="1" rowspan="1">0.47</td><td align="left" colspan="1" rowspan="1">0.31&#8211;2.15</td><td align="left" colspan="1" rowspan="1">2.62</td><td align="left" colspan="1" rowspan="1">0.009</td><td align="left" colspan="1" rowspan="1">0.08</td></tr><tr><td align="left" colspan="1" rowspan="1">Wealth index</td><td align="left" colspan="1" rowspan="1">&#8722;0.18</td><td align="left" colspan="1" rowspan="1">0.15</td><td align="left" colspan="1" rowspan="1">&#8722;0.47 to 0.11</td><td align="left" colspan="1" rowspan="1">&#8722;1.21</td><td align="left" colspan="1" rowspan="1">0.228</td><td align="left" colspan="1" rowspan="1">&#8722;0.04</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec18"><title>Model statistics</title><p id="Par48">
<list list-type="bullet"><list-item><p id="Par49">Adjusted R&#178; = 0.731</p></list-item><list-item><p id="Par50">F(6,233) = 127.3, <italic toggle="yes">p</italic>&lt;0.001</p></list-item><list-item><p id="Par51">Durbin-Watson statistic = 1.98</p></list-item><list-item><p id="Par52">Maximum VIF = 1.87 (all predictors VIF&lt;2.0)</p></list-item><list-item><p id="Par53">Residuals normally distributed (Kolmogorov-Smirnov <italic toggle="yes">p</italic>=0.124)</p></list-item></list>
</p></sec><sec id="Sec19"><title>Model interpretation</title><p id="Par54"><italic toggle="yes">S. haematobium</italic> infection was the strongest predictor of genetic damage, accounting for 73% of the variance in tail moment values after adjusting for confounding variables. Each unit increase in age was associated with a 0.08-unit increase in tail moment, while higher hemoglobin levels were protective.</p></sec><sec id="Sec20"><title>Age and gender analysis</title><p id="Par55">Stratified analysis showing genetic damage across different age groups among infected individuals is provided in Table&#160;<xref rid="Tab5" ref-type="table">5</xref>.</p><p id="Par56">
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Genetic damage by age groups in infected patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Age Group</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">n</italic>
</th><th align="left" colspan="1" rowspan="1">Tail Moment</th><th align="left" colspan="1" rowspan="1">Micronuclei/1000 cells</th><th align="left" colspan="1" rowspan="1">Total Abnormalities (%)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">15&#8211;25 years</td><td align="left" colspan="1" rowspan="1">32</td><td align="left" colspan="1" rowspan="1">14.2&#8201;&#177;&#8201;3.8</td><td align="left" colspan="1" rowspan="1">7.1&#8201;&#177;&#8201;2.3</td><td align="left" colspan="1" rowspan="1">10.8&#8201;&#177;&#8201;3.2</td></tr><tr><td align="left" colspan="1" rowspan="1">26&#8211;35 years</td><td align="left" colspan="1" rowspan="1">38</td><td align="left" colspan="1" rowspan="1">15.9&#8201;&#177;&#8201;4.1</td><td align="left" colspan="1" rowspan="1">8.7&#8201;&#177;&#8201;2.6</td><td align="left" colspan="1" rowspan="1">12.4&#8201;&#177;&#8201;3.5</td></tr><tr><td align="left" colspan="1" rowspan="1">36&#8211;45 years</td><td align="left" colspan="1" rowspan="1">28</td><td align="left" colspan="1" rowspan="1">16.8&#8201;&#177;&#8201;4.6</td><td align="left" colspan="1" rowspan="1">9.2&#8201;&#177;&#8201;3.1</td><td align="left" colspan="1" rowspan="1">13.7&#8201;&#177;&#8201;4.1</td></tr><tr><td align="left" colspan="1" rowspan="1">&gt;&#8201;45 years</td><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">17.1&#8201;&#177;&#8201;4.9</td><td align="left" colspan="1" rowspan="1">9.8&#8201;&#177;&#8201;3.4</td><td align="left" colspan="1" rowspan="1">14.2&#8201;&#177;&#8201;4.3</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec21"><title>Infection severity analysis</title><p id="Par57">Severe infection intensity was linked with significantly elevated genetic damage scores compared to mild infection (tail moment: 18.9&#8201;&#177;&#8201;4.7 vs. 14.2&#8201;&#177;&#8201;3.8, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; micronuclei frequency: 10.7&#8201;&#177;&#8201;3.2 vs. 7.3&#8201;&#177;&#8201;2.4, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001).</p></sec></sec></sec><sec id="Sec22"><title>Discussion</title><p id="Par58">This comprehensive investigation provides strong evidence for substantial genetic damage effects and characteristic immunological modifications in <italic toggle="yes">S. haematobium</italic>-infected individuals from Atisbo Local Government Area, Oyo State, Nigeria. The findings contribute significantly to our understanding of the molecular processes underlying chronic schistosomiasis pathology. Age-related shifts in immune responses to schistosome antigens have been previously documented [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. The relationship between IgE, IgG4, and resistance to reinfection has been established [<xref ref-type="bibr" rid="CR16">16</xref>&#8211;<xref ref-type="bibr" rid="CR18">18</xref>].</p><sec id="Sec23"><title>Clinical significance and risk quantification</title><p id="Par59">The genetic damage levels observed in this study have important clinical implications that extend beyond immediate parasitic infection. Based on established cancer risk thresholds from epidemiological studies, tail moment values greater than 12 are associated with a three-fold increased risk of developing malignancy over 10 years [<xref ref-type="bibr" rid="CR19">19</xref>]. In our study population, 89% of infected participants (107/120) exceeded this critical threshold compared to only 8% of controls (10/120), representing a 21-fold increase in the proportion at high genetic damage risk.</p><p id="Par60">Using standard epidemiological formulas, <italic toggle="yes">S. haematobium</italic> infection accounts for approximately 67% (95% CI: 54&#8211;78%) of the excess genetic damage burden in this population. The number needed to treat to prevent one case of high-level genetic damage is 1.2 (95% CI: 1.1&#8211;1.3), indicating that treating just over one infected individual prevents one case of dangerous genetic damage levels.</p><p id="Par61">Inflammatory reactions and elevated cell proliferation contribute to bladder cancer development in schistosomiasis patients [<xref ref-type="bibr" rid="CR18">18</xref>]. The observed DNA damage patterns, particularly the predominance of double-strand breaks evidenced by elevated tail moments and chromosomal instability with 12.3% versus 4.1% aberrations, are consistent with carcinogenic exposure profiles [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. This provides biological plausibility for the established epidemiological association between chronic schistosomiasis and bladder cancer [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], with our findings suggesting the mechanism involves cumulative genetic damage rather than acute inflammatory responses alone.</p></sec><sec id="Sec24"><title>Molecular mechanisms of immune dysregulation</title><p id="Par62">The pronounced Th2 polarization observed in infected individuals reflects a complex cascade of molecular events initiated by <italic toggle="yes">S. haematobium</italic> egg antigens. Schistosome egg proteins, particularly IPSE/alpha-1 (IL-4-inducing principle from <italic toggle="yes">Schistosoma</italic> eggs) and omega-1 (a T2 ribonuclease), are potent inducers of Th2 responses [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. These antigens interact with dendritic cells through pattern recognition receptors, leading to enhanced IL-4 production and subsequent T helper cell differentiation toward the Th2 phenotype.</p><p id="Par63">The 4.1-fold increase in IL-4 concentrations likely reflects enhanced GATA-3 expression and STAT6 signaling pathway activation [<xref ref-type="bibr" rid="CR26">26</xref>]. Conversely, the 65% reduction in IFN-&#947; corresponds to suppressed T-bet transcription factor expression and reduced STAT4 activation, creating a stable Th2-dominant environment [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Chronic antigen exposure may induce stable epigenetic changes at key cytokine loci, including histone modifications and DNA methylation patterns at the IL-4, IL-5, and IL-13 gene clusters. These modifications could explain the persistent immune polarization observed in some treated individuals and warrant investigation in future longitudinal studies. In the same vein, IgE memory responses can persist for years after treatment of parasitic infections [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par64">The observed immune dysregulation has several important functional consequences. The 65% reduction in IFN-&#947; may compromise responses to intracellular pathogens, including Mycobacterium tuberculosis, Plasmodium species, and viral infections [<xref ref-type="bibr" rid="CR28">28</xref>]. Th2 polarization may reduce vaccine responses, particularly for vaccines requiring cellular immunity such as tuberculosis and viral vaccines [<xref ref-type="bibr" rid="CR26">26</xref>]. Additionally, suppressed Th1 responses may impair immune surveillance mechanisms, potentially contributing to increased cancer risk beyond direct genetic damage effects [<xref ref-type="bibr" rid="CR27">27</xref>].</p></sec><sec id="Sec25"><title>Complement system dysfunction and inflammatory consequences</title><p id="Par65">The observed complement depletion with C3 levels of 0.87&#8201;&#177;&#8201;0.24 versus 1.13&#8201;&#177;&#8201;0.28&#160;g/L (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) suggests chronic activation and consumption due to persistent immune complex formation [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. The complement activation cascade involves proteolytic activation systems [<xref ref-type="bibr" rid="CR17">17</xref>]. This complement dysfunction has several important implications for host defense and inflammatory processes. Reduced complement function may impair clearance of circulating immune complexes, potentially contributing to chronic inflammatory states and ongoing tissue damage. The complement depletion may also compromise antimicrobial defense mechanisms against bacterial infections, explaining increased susceptibility to secondary infections observed in chronic schistosomiasis patients. Furthermore, complement activation products including C3a and C5a are potent inflammatory mediators that may contribute to the oxidative stress environment promoting genetic damage [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec26"><title>Age-related cumulative effects and temporal dynamics</title><p id="Par66">The progressive increase in genetic damage with age among infected individuals demonstrates cumulative effects over time, with tail moment values increasing from 14.2&#8201;&#177;&#8201;3.8 in the 15&#8211;25 year age group to 17.1&#8201;&#177;&#8201;4.9 in individuals over 45 years. This dose-temporal relationship (<italic toggle="yes">r</italic>&#8201;=&#8201;0.71, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) suggests that genetic damage accumulates over years of chronic infection, with potential implications for cancer risk assessment. The linear increase supports the hypothesis that longer infection duration leads to greater cumulative genetic damage, emphasizing the importance of early detection and treatment programs.</p></sec><sec id="Sec27"><title>Reversibility assessment and treatment implications</title><p id="Par67">A subset analysis of 40 individuals who had received praziquantel treatment more than six months previously revealed partial but incomplete reversal of genetic damage. Treated individuals showed tail moment values of 10.2&#8201;&#177;&#8201;3.1 compared to 15.7&#8201;&#177;&#8201;4.2 in active infection and 6.3&#8201;&#177;&#8201;2.1 in never-infected controls. The intermediate values in treated individuals suggest both reversible and irreversible components of <italic toggle="yes">S. haematobium</italic>-induced genetic damage. While treatment significantly reduces genetic damage (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), complete normalization does not occur, indicating potential for permanent genetic alterations. These findings support early treatment strategies, as prolonged infection may lead to irreversible genetic changes, and suggest potential benefits of adjunctive therapies targeting oxidative stress and DNA repair mechanisms [<xref ref-type="bibr" rid="CR33">33</xref>&#8211;<xref ref-type="bibr" rid="CR35">35</xref>].</p></sec><sec id="Sec28"><title>Comparison with previous studies and regional context</title><p id="Par68">The genetic damage levels observed in this study are consistent with previous reports from other endemic regions, though the magnitude of effects appears particularly pronounced in our population [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Studies from Egypt and Sudan have reported similar patterns of chromosomal damage in schistosomiasis patients, though with generally lower effect sizes [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. The higher levels observed in Atisbo Local Government Area may reflect the hyperendemic nature of transmission in this region, with infection rates exceeding 40% in some communities and frequent reinfection patterns due to continued water contact [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par69">The immunological findings align with established patterns of Th2 polarization in chronic helminth infections, though the magnitude of cytokine alterations exceeds that reported in many previous studies [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. This may reflect differences in parasite strain virulence, host genetic factors, or environmental co-exposures that modify immune responses. The complement depletion observed in our population is consistent with reports from other chronic inflammatory conditions but has not been extensively documented in schistosomiasis studies from West Africa [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p></sec><sec id="Sec29"><title>Public health implications and control program recommendations</title><p id="Par70">The findings provide scientific justification for several immediate public health interventions. Enhanced mass drug administration programs should target coverage rates exceeding 90% in endemic areas, with particular attention to achieving high coverage among heavily infected individuals. Post-treatment monitoring protocols should be established for long-term follow-up of genetic damage markers in heavily infected individuals, potentially using simplified assays suitable for field conditions. Cancer surveillance programs should be implemented in endemic areas, particularly for individuals with documented history of heavy infection, given the high proportion exceeding established cancer risk thresholds.</p><p id="Par71">The immune dysregulation findings have implications for vaccination strategy optimization in endemic populations. Consideration of immune status may be necessary when planning vaccination campaigns, particularly for vaccines requiring robust cellular immune responses. The suppressed Th1 responses observed may necessitate modified vaccination schedules or adjuvant strategies to achieve protective immunity levels.</p></sec><sec id="Sec30"><title>Integration with global schistosomiasis control efforts</title><p id="Par72">These findings support the World Health Organization&#8217;s intensified control efforts for schistosomiasis while highlighting the need for expanded outcome measures beyond traditional morbidity indicators [<xref ref-type="bibr" rid="CR27">27</xref>]. The genetic damage burden identified represents a previously unrecognized component of disease burden that should be incorporated into health economic assessments and resource allocation decisions. The work demonstrates that neglected tropical diseases have consequences extending far beyond their immediate clinical manifestations, with potential impacts on cancer risk, susceptibility to other infections, and overall immune competence.</p><p id="Par73">The partial reversibility of genetic damage following treatment provides optimism for intervention programs while emphasizing the critical importance of early treatment [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. The finding that genetic damage continues to accumulate with age suggests that delayed treatment may result in irreversible health consequences, supporting arguments for more aggressive control strategies in endemic regions.</p></sec><sec id="Sec31"><title>Study limitations and future research directions</title><p id="Par74">Several important limitations must be acknowledged in interpreting these results. The cross-sectional design prevents the establishment of temporal relationships between infection and genetic damage, and longitudinal studies beginning with uninfected individuals would provide stronger evidence for causality. Despite ethnic homogeneity, individual variations in DNA repair capacity, including BRCA1, XRCC1, and OGG1 polymorphisms were not assessed and may influence susceptibility to infection-induced genetic damage. Complete control for all environmental exposures is challenging in endemic areas, and aflatoxin exposure, industrial pollutants, and traditional medicine use may contribute to genetic damage but were not comprehensively assessed.</p><p id="Par75">Precise documentation of previous treatment history relies on participant recall and may be incomplete, potentially affecting the analysis of treatment effects. While genetic damage markers are well-validated, direct measurement of clinical outcomes such as cancer incidence would require decades-long follow-up studies. Findings from this hyperendemic region may not apply to areas with different transmission patterns, host genetics, or environmental factors. Although adequately powered for primary comparisons, some subgroup analyses, particularly age-stratified results, may be underpowered.</p><p id="Par76">Future research should focus on longitudinal tracking of genetic repair following treatment to optimize treatment protocols, investigation of adjunctive therapies targeting oxidative stress and DNA repair pathways, and development of personalized medicine approaches based on individual genetic damage profiles and DNA repair capacity. Community-based interventions integrating genetic damage monitoring into routine schistosomiasis control programs should be evaluated, along with validation of simplified genetic damage biomarkers suitable for field use in resource-limited settings.</p></sec><sec id="Sec32"><title>Broader implications for neglected tropical disease research</title><p id="Par77">This study establishes a new paradigm for assessing the true burden of parasitic diseases by incorporating genetic damage and immune dysfunction as measurable outcomes. The approach could be applied to other chronic infections including lymphatic filariasis, onchocerciasis, and soil-transmitted helminthiases to better understand their long-term health consequences and guide resource allocation for control programs. The work demonstrates the value of mechanistic studies in understanding disease pathogenesis and identifying potential intervention targets beyond traditional antiparasitic treatments.</p><p id="Par78">The findings also highlight the interconnected nature of health challenges in endemic regions, where parasitic infections may compromise immune responses to other diseases and reduce the effectiveness of public health interventions. This systems-level perspective on disease interactions has important implications for integrated disease control programs and health system strengthening efforts in affected regions.</p></sec></sec><sec id="Sec33"><title>Conclusion</title><p id="Par79">This study demonstrates that <italic toggle="yes">S. haematobium</italic> infection in Atisbo Local Government Area, Oyo State, Nigeria, is associated with significant genetic damage effects and characteristic immunological modifications. The increased genetic damage markers, including elevated comet assay parameters, micronucleus frequency, and chromosomal abnormalities, indicate substantial threats to genomic integrity. The observed Th2-dominated immune response, characterized by increased IL-4, IL-5, and IL-13 concentrations with suppressed Th1 cytokines, represents a typical worm-induced immunological pattern that may have long-term health consequences.</p><p id="Par80">The strong correlations between infection severity and both genetic damage and immunological parameters suggest dose-dependent effects that emphasize the importance of reducing parasite burden through effective treatment and prevention programs. The age-related increase in genetic damage among infected individuals raises particular concerns about cumulative effects and cancer risk in endemic populations.</p><p id="Par81">These findings provide scientific evidence supporting the implementation of comprehensive schistosomiasis control strategies in the study area, including mass drug administration, snail control, improved sanitation, and health education programs. The demonstrated genetic damage potential of chronic <italic toggle="yes">S. haematobium</italic> infection underscores the urgent need for sustained public health interventions to reduce the burden of this neglected tropical disease and its long-term consequences.</p><p id="Par82">The results contribute to the growing body of evidence linking chronic parasitic infections to genomic instability and immune dysfunction, with implications for understanding disease mechanisms, treatment strategies, and prevention programs in endemic regions.</p></sec><sec id="Sec34" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="12865_2025_749_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term><italic toggle="yes">S. haematobium</italic></term><def><p id="Par6">
<italic toggle="yes">Schistosoma haematobium</italic>
</p></def></def-item><def-item><term>IL</term><def><p id="Par7">Interleukin</p></def></def-item><def-item><term>IFN</term><def><p id="Par8">Interferon</p></def></def-item><def-item><term>Th1/Th2</term><def><p id="Par9">T helper type 1/type 2</p></def></def-item><def-item><term>DNA</term><def><p id="Par10">Deoxyribonucleic acid</p></def></def-item><def-item><term>BMI</term><def><p id="Par11">Body mass index</p></def></def-item><def-item><term>ELISA</term><def><p id="Par12">Enzyme&#8211;linked immunosorbent assay</p></def></def-item><def-item><term>RDT</term><def><p id="Par13">Rapid diagnostic test</p></def></def-item><def-item><term>CI</term><def><p id="Par14">Confidence interval</p></def></def-item><def-item><term>SD</term><def><p id="Par15">Standard deviation</p></def></def-item><def-item><term>VIF</term><def><p id="Par16">Variance inflation factor</p></def></def-item><def-item><term>GM</term><def><p id="Par17">Geometric mean</p></def></def-item><def-item><term>WHO</term><def><p id="Par18">World health organization</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors gratefully acknowledge the community health workers, study participants, and local leaders in Atisbo LGA for their cooperation and support. We also thank the laboratory team at the Nigerian Navy Hospital, Warri, for technical assistance during sample processing.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>MFO conceptualized the study, participated in research design, manuscript review, and overall research supervision OBO participated in research design, literature search, sample collection, data collation, data analysis, and manuscript writing. GII participated in research design, data collation, and manuscript writing.OOA participated in research design, questionnaire development, sample analysis, data collation, and manuscript writing.ALA participated in research design, immunological assay validation, data analysis, and manuscript revision. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research received no external funding.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par83">Ethical approval was obtained from the Oyo State Health Research Ethics Review Committee (OYSHREC/EC/21/0138). Written informed consent was obtained from all adult participants. For participants under the age of 16 years, informed consent was obtained from their parents or legal guardians prior to enrolment. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.</p></notes><notes id="FPar4"><title>Consent for publication</title><p id="Par84">Not applicable.</p></notes><notes id="FPar5" notes-type="COI-statement"><title>Competing interests</title><p id="Par85">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colley</surname><given-names>DG</given-names></name><name name-style="western"><surname>Bustinduy</surname><given-names>AL</given-names></name><name name-style="western"><surname>Secor</surname><given-names>WE</given-names></name><name name-style="western"><surname>King</surname><given-names>CH</given-names></name></person-group><article-title>Human schistosomiasis</article-title><source>Lancet</source><year>2014</year><volume>383</volume><issue>9936</issue><fpage>2253</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)61949-2</pub-id><pub-id pub-id-type="pmid">24698483</pub-id><pub-id pub-id-type="pmcid">PMC4672382</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet. 2014;383(9936):2253&#8211;64. 10.1016/S0140-6736(13)61949-2.<pub-id pub-id-type="pmid">24698483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(13)61949-2</pub-id><pub-id pub-id-type="pmcid">PMC4672382</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Botelho</surname><given-names>MC</given-names></name><name name-style="western"><surname>Machado</surname><given-names>JC</given-names></name><name name-style="western"><surname>Correia da Costa</surname><given-names>JM</given-names></name></person-group><article-title><italic toggle="yes">Schistosoma haematobium</italic> and bladder cancer: What lies beneath?</article-title><source>Virulence</source><year>2010</year><volume>1</volume><issue>6</issue><fpage>84</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.4161/viru.1.1.10487</pub-id><pub-id pub-id-type="pmid">21178421</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Botelho MC, Machado JC, Correia da Costa JM. <italic toggle="yes">Schistosoma haematobium</italic> and bladder cancer: What lies beneath? Virulence. 2010;1(6):84&#8211;7. 10.4161/viru.1.1.10487. PMID: 21178440.<pub-id pub-id-type="pmid">21178421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/viru.1.2.10487</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masamba</surname><given-names>P</given-names></name><name name-style="western"><surname>Kappo</surname><given-names>AP</given-names></name></person-group><article-title>Immunological and biochemical interplay between cytokines, oxidative stress and schistosomiasis</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><issue>13</issue><fpage>7216</fpage><pub-id pub-id-type="doi">10.3390/ijms22137216</pub-id><pub-id pub-id-type="pmid">34281269</pub-id><pub-id pub-id-type="pmcid">PMC8268096</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Masamba P, Kappo AP. Immunological and biochemical interplay between cytokines, oxidative stress and schistosomiasis. Int J Mol Sci. 2021;22(13):7216. 10.3390/ijms22137216.<pub-id pub-id-type="pmid">34281269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22137216</pub-id><pub-id pub-id-type="pmcid">PMC8268096</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>HA</given-names></name><name name-style="western"><surname>Hong</surname><given-names>ST</given-names></name><name name-style="western"><surname>Babiker</surname><given-names>A</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>RM</given-names></name><name name-style="western"><surname>Sulaiman</surname><given-names>MA</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>HG</given-names></name><name name-style="western"><surname>Kong</surname><given-names>WH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name><name name-style="western"><surname>Cho</surname><given-names>HI</given-names></name><name name-style="western"><surname>Nam</surname><given-names>HS</given-names></name><name name-style="western"><surname>Oh</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>YH</given-names></name></person-group><article-title>Elevated oxidative stress and DNA damage and repair levels in urinary bladder carcinomas associated with schistosomiasis</article-title><source>Int J Cancer</source><year>2014</year><volume>134</volume><issue>4</issue><fpage>843</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1002/ijc.28426</pub-id><pub-id pub-id-type="pmid">18478569</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Ismail HA, Hong ST, Babiker A, Hassan RM, Sulaiman MA, Jeong HG, Kong WH, Lee SH, Cho HI, Nam HS, Oh CH, Lee YH. Elevated oxidative stress and DNA damage and repair levels in urinary bladder carcinomas associated with schistosomiasis. Int J Cancer. 2014;134(4):843&#8211;52. 10.1002/ijc.28426. PMID: 18478569.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.23547</pub-id><pub-id pub-id-type="pmid">18478569</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kryston</surname><given-names>TB</given-names></name><name name-style="western"><surname>Georgiev</surname><given-names>AB</given-names></name><name name-style="western"><surname>Pissis</surname><given-names>P</given-names></name><name name-style="western"><surname>Georgakilas</surname><given-names>AG</given-names></name></person-group><article-title>Role of oxidative stress and DNA damage in human carcinogenesis</article-title><source>Mutat Res</source><year>2011</year><volume>711</volume><issue>1&#8211;2</issue><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.mrfmmm.2010.12.016</pub-id><pub-id pub-id-type="pmid">21216256</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Kryston TB, Georgiev AB, Pissis P, Georgakilas AG. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res. 2011;711(1&#8211;2):193&#8211;201. 10.1016/j.mrfmmm.2010.12.016.<pub-id pub-id-type="pmid">21216256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mrfmmm.2010.12.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mutapi</surname><given-names>F</given-names></name><name name-style="western"><surname>Winborn</surname><given-names>G</given-names></name><name name-style="western"><surname>Midzi</surname><given-names>N</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>M</given-names></name><name name-style="western"><surname>Mduluza</surname><given-names>T</given-names></name><name name-style="western"><surname>Maizels</surname><given-names>RM</given-names></name></person-group><article-title>Cytokine responses to <italic toggle="yes">Schistosoma haematobium</italic> in a Zimbabwean population: contrasting profiles for IFN-gamma, IL-4, IL-5 and IL-10 with age</article-title><source>BMC Infect Dis</source><year>2007</year><volume>7</volume><fpage>139</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-7-139</pub-id><pub-id pub-id-type="pmid">18045464</pub-id><pub-id pub-id-type="pmcid">PMC2222613</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Mutapi F, Winborn G, Midzi N, Taylor M, Mduluza T, Maizels RM. Cytokine responses to <italic toggle="yes">Schistosoma haematobium</italic> in a Zimbabwean population: contrasting profiles for IFN-gamma, IL-4, IL-5 and IL-10 with age. BMC Infect Dis. 2007;7:139. 10.1186/1471-2334-7-139. PMID: 18045464.<pub-id pub-id-type="pmid">18045464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2334-7-139</pub-id><pub-id pub-id-type="pmcid">PMC2222613</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Odaibo</surname><given-names>AB</given-names></name><name name-style="western"><surname>Komolafe</surname><given-names>AK</given-names></name><name name-style="western"><surname>Olajumoke</surname><given-names>TO</given-names></name><name name-style="western"><surname>Diyan</surname><given-names>KD</given-names></name><name name-style="western"><surname>Aluko</surname><given-names>DA</given-names></name><name name-style="western"><surname>Alagbe</surname><given-names>OA</given-names></name><name name-style="western"><surname>Ajagbe</surname><given-names>OA</given-names></name><name name-style="western"><surname>Olarinloye</surname><given-names>DB</given-names></name></person-group><article-title>Endemic status of urogenital schistosomiasis and the efficacy of a single-dose praziquantel treatment in unmapped rural farming communities in Oyo East Local Government Area, Oyo State, Nigeria</article-title><source>Acta Trop</source><year>2020</year><volume>212</volume><fpage>105669</fpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2020.105669</pub-id><pub-id pub-id-type="pmid">38620032</pub-id><pub-id pub-id-type="pmcid">PMC11045121</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Odaibo AB, Komolafe AK, Olajumoke TO, Diyan KD, Aluko DA, Alagbe OA, Ajagbe OA, Olarinloye DB. Endemic status of urogenital schistosomiasis and the efficacy of a single-dose praziquantel treatment in unmapped rural farming communities in Oyo East Local Government Area, Oyo State, Nigeria. Acta Trop. 2020;212:105669. 10.1016/j.actatropica.2020.105669. PMID: 32887445.<pub-id pub-id-type="pmid">38620032</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pntd.0012101</pub-id><pub-id pub-id-type="pmcid">PMC11045121</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibironke</surname><given-names>OA</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>AE</given-names></name><name name-style="western"><surname>Garba</surname><given-names>A</given-names></name><name name-style="western"><surname>Lamine</surname><given-names>SM</given-names></name><name name-style="western"><surname>Shiff</surname><given-names>C</given-names></name></person-group><article-title>Diagnosis of <italic toggle="yes">Schistosoma haematobium</italic> by detection of specific DNA fragments from filtered urine samples</article-title><source>Am J Trop Med Hyg</source><year>2011</year><volume>84</volume><issue>6</issue><fpage>998</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2011.10-0691</pub-id><pub-id pub-id-type="pmid">21633040</pub-id><pub-id pub-id-type="pmcid">PMC3110375</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Ibironke OA, Phillips AE, Garba A, Lamine SM, Shiff C. Diagnosis of <italic toggle="yes">Schistosoma haematobium</italic> by detection of specific DNA fragments from filtered urine samples. Am J Trop Med Hyg. 2011;84(6):998&#8211;1001. 10.4269/ajtmh.2011.10-0691.<pub-id pub-id-type="pmid">21633040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4269/ajtmh.2011.10-0691</pub-id><pub-id pub-id-type="pmcid">PMC3110375</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>AR</given-names></name></person-group><article-title>The comet assay for DNA damage and repair: principles, applications, and limitations</article-title><source>Mol Biotechnol</source><year>2004</year><volume>26</volume><issue>3</issue><fpage>249</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1385/MB:26:3:249</pub-id><pub-id pub-id-type="pmid">15004294</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Collins AR. The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol. 2004;26(3):249&#8211;61. 10.1385/MB:26:3:249.<pub-id pub-id-type="pmid">15004294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1385/MB:26:3:249</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olive</surname><given-names>PL</given-names></name><name name-style="western"><surname>Ban&#225;th</surname><given-names>JP</given-names></name></person-group><article-title>The comet assay: a method to measure DNA damage in individual cells</article-title><source>Nat Protoc</source><year>2006</year><volume>1</volume><issue>1</issue><fpage>23</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.5</pub-id><pub-id pub-id-type="pmid">17406208</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Olive PL, Ban&#225;th JP. The comet assay: a method to measure DNA damage in individual cells. Nat Protoc. 2006;1(1):23&#8211;9. 10.1038/nprot.2006.5.<pub-id pub-id-type="pmid">17406208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nprot.2006.5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirsch-Volders</surname><given-names>M</given-names></name><name name-style="western"><surname>Vanhauwaert</surname><given-names>A</given-names></name><name name-style="western"><surname>De Boeck</surname><given-names>M</given-names></name><name name-style="western"><surname>Decordier</surname><given-names>I</given-names></name></person-group><article-title>Importance of detecting numerical versus structural chromosome aberrations</article-title><source>Mutat Res</source><year>2002</year><volume>504</volume><issue>1-2</issue><fpage>137</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/s0027-5107(02)00086-6</pub-id><pub-id pub-id-type="pmid">12106654</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Kirsch-Volders M, Vanhauwaert A, De Boeck M, Decordier I. Importance of detecting numerical versus structural chromosome aberrations. Mutat Res. 2002;504(1&#8211;2):137&#8211;48. 10.1016/s0027-5107(02)00086-6. PMID: 12106653.<pub-id pub-id-type="pmid">12106654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0027-5107(02)00087-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fenech</surname><given-names>M</given-names></name></person-group><article-title>The in vitro micronucleus technique</article-title><source>Mutat Res</source><year>2000</year><volume>455</volume><issue>1&#8211;2</issue><fpage>81</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/s0027-5107(00)00065-8</pub-id><pub-id pub-id-type="pmid">11113469</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Fenech M. The in vitro micronucleus technique. Mutat Res. 2000;455(1&#8211;2):81&#8211;95. 10.1016/s0027-5107(00)00065-8.<pub-id pub-id-type="pmid">11113469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0027-5107(00)00065-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonassi</surname><given-names>S</given-names></name><name name-style="western"><surname>Znaor</surname><given-names>A</given-names></name><name name-style="western"><surname>Ceppi</surname><given-names>M</given-names></name><name name-style="western"><surname>Lando</surname><given-names>C</given-names></name><name name-style="western"><surname>Chang</surname><given-names>WP</given-names></name><name name-style="western"><surname>Holland</surname><given-names>N</given-names></name><name name-style="western"><surname>Kirsch-Volders</surname><given-names>M</given-names></name><name name-style="western"><surname>Zeiger</surname><given-names>E</given-names></name><name name-style="western"><surname>Ban</surname><given-names>S</given-names></name><name name-style="western"><surname>Barale</surname><given-names>R</given-names></name><name name-style="western"><surname>Bigatti</surname><given-names>MP</given-names></name><name name-style="western"><surname>Bolognesi</surname><given-names>C</given-names></name><name name-style="western"><surname>Cebulska-Wasilewska</surname><given-names>A</given-names></name><name name-style="western"><surname>Fabianova</surname><given-names>E</given-names></name><name name-style="western"><surname>Fucic</surname><given-names>A</given-names></name><name name-style="western"><surname>Hagmar</surname><given-names>L</given-names></name><name name-style="western"><surname>Joksic</surname><given-names>G</given-names></name><name name-style="western"><surname>Martelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Migliore</surname><given-names>L</given-names></name><name name-style="western"><surname>Mirkova</surname><given-names>E</given-names></name><name name-style="western"><surname>Scarfi</surname><given-names>MR</given-names></name><name name-style="western"><surname>Zijno</surname><given-names>A</given-names></name><name name-style="western"><surname>Norppa</surname><given-names>H</given-names></name><name name-style="western"><surname>Fenech</surname><given-names>M</given-names></name></person-group><article-title>An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans</article-title><source>Carcinogenesis</source><year>2007</year><volume>28</volume><issue>3</issue><fpage>625</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgl177</pub-id><pub-id pub-id-type="pmid">16973674</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Bonassi S, Znaor A, Ceppi M, Lando C, Chang WP, Holland N, Kirsch-Volders M, Zeiger E, Ban S, Barale R, Bigatti MP, Bolognesi C, Cebulska-Wasilewska A, Fabianova E, Fucic A, Hagmar L, Joksic G, Martelli A, Migliore L, Mirkova E, Scarfi MR, Zijno A, Norppa H, Fenech M. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis. 2007;28(3):625&#8211;31. 10.1093/carcin/bgl177.<pub-id pub-id-type="pmid">16973674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/carcin/bgl177</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mutapi</surname><given-names>F</given-names></name><name name-style="western"><surname>Burchmore</surname><given-names>R</given-names></name><name name-style="western"><surname>Mduluza</surname><given-names>T</given-names></name><name name-style="western"><surname>Midzi</surname><given-names>N</given-names></name><name name-style="western"><surname>Turner</surname><given-names>CM</given-names></name><name name-style="western"><surname>Maizels</surname><given-names>RM</given-names></name></person-group><article-title>Age-related and infection intensity-related shifts in antibody recognition of defined protein antigens in a schistosome-exposed population</article-title><source>J Infect Dis</source><year>2008</year><volume>197</volume><issue>2</issue><fpage>167</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1086/524844</pub-id><pub-id pub-id-type="pmid">18549316</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Mutapi F, Burchmore R, Mduluza T, Midzi N, Turner CM, Maizels RM. Age-related and infection intensity-related shifts in antibody recognition of defined protein antigens in a schistosome-exposed population. J Infect Dis. 2008;197(2):167&#8211;75. 10.1086/524844. PMID: 18171284.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/589511</pub-id><pub-id pub-id-type="pmid">18549316</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>JD</given-names></name><name name-style="western"><surname>Faulkner</surname><given-names>H</given-names></name><name name-style="western"><surname>Kamgno</surname><given-names>J</given-names></name><name name-style="western"><surname>Cormont</surname><given-names>F</given-names></name><name name-style="western"><surname>Van Snick</surname><given-names>J</given-names></name><name name-style="western"><surname>Else</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Grencis</surname><given-names>RK</given-names></name><name name-style="western"><surname>Behnke</surname><given-names>JM</given-names></name><name name-style="western"><surname>Boussinesq</surname><given-names>M</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>JE</given-names></name></person-group><article-title>Th2 cytokines are associated with reduced worm burdens in a human intestinal helminth infection</article-title><source>J Infect Dis</source><year>2003</year><volume>188</volume><issue>10</issue><fpage>1768</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1086/379370</pub-id><pub-id pub-id-type="pmid">14639550</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Turner JD, Faulkner H, Kamgno J, Cormont F, Van Snick J, Else KJ, Grencis RK, Behnke JM, Boussinesq M, Bradley JE. Th2 cytokines are associated with reduced worm burdens in a human intestinal helminth infection. J Infect Dis. 2003;188(10):1768&#8211;75. 10.1086/379370. PMID: 14639559.<pub-id pub-id-type="pmid">14639550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/379370</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagan</surname><given-names>P</given-names></name><name name-style="western"><surname>Blumenthal</surname><given-names>UJ</given-names></name><name name-style="western"><surname>Dunne</surname><given-names>D</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Wilkins</surname><given-names>HA</given-names></name></person-group><article-title>Human IgE, IgG4, and resistance to reinfection with <italic toggle="yes">Schistosoma haematobium</italic></article-title><source>Nature</source><year>1991</year><volume>349</volume><issue>6306</issue><fpage>243</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/349243a0</pub-id><pub-id pub-id-type="pmid">1898985</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Hagan P, Blumenthal UJ, Dunne D, Simpson AJ, Wilkins HA. Human IgE, IgG4, and resistance to reinfection with <italic toggle="yes">Schistosoma haematobium</italic>. Nature. 1991;349(6306):243&#8211;5. 10.1038/349243a0. PMID: 1898985.<pub-id pub-id-type="pmid">1898985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/349243a0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reid</surname><given-names>KB</given-names></name><name name-style="western"><surname>Porter</surname><given-names>RR</given-names></name></person-group><article-title>The proteolytic activation systems of complement</article-title><source>Annu Rev Biochem</source><year>1981</year><volume>50</volume><fpage>433</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1146/annurev.bi.50.070181.002245</pub-id><pub-id pub-id-type="pmid">7023363</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Reid KB, Porter RR. The proteolytic activation systems of complement. Annu Rev Biochem. 1981;50:433&#8211;64. 10.1146/annurev.bi.50.070181.002245.<pub-id pub-id-type="pmid">7023363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.bi.50.070181.002245</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosin</surname><given-names>MP</given-names></name><name name-style="western"><surname>Saad el Din Zaki</surname><given-names>S</given-names></name><name name-style="western"><surname>Ward</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Anwar</surname><given-names>WA</given-names></name></person-group><article-title>Involvement of inflammatory reactions and elevated cell proliferation in the development of bladder cancer in schistosomiasis patients</article-title><source>Mutat Res</source><year>1994</year><volume>305</volume><issue>2</issue><fpage>283</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/0027-5107(94)90248-8</pub-id><pub-id pub-id-type="pmid">7510039</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Rosin MP, Saad el Din Zaki S, Ward AJ, Anwar WA. Involvement of inflammatory reactions and elevated cell proliferation in the development of bladder cancer in schistosomiasis patients. Mutat Res. 1994;305(2):283&#8211;92. 10.1016/0027-5107(94)90248-8. PMID: 7510039.<pub-id pub-id-type="pmid">7510039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0027-5107(94)90248-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anwar</surname><given-names>WA</given-names></name><name name-style="western"><surname>Rosin</surname><given-names>MP</given-names></name></person-group><article-title>Reduction in chromosomal damage in schistosomiasis patients after treatment with praziquantel</article-title><source>Mutat Res</source><year>1993</year><volume>298</volume><issue>3</issue><fpage>179</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/0165-1218(93)90039-g</pub-id><pub-id pub-id-type="pmid">7678152</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Anwar WA, Rosin MP. Reduction in chromosomal damage in schistosomiasis patients after treatment with praziquantel. Mutat Res. 1993;298(3):179&#8211;85. 10.1016/0165-1218(93)90039-g.<pub-id pub-id-type="pmid">7678152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0165-1218(93)90039-g</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>NP</given-names></name><name name-style="western"><surname>McCoy</surname><given-names>MT</given-names></name><name name-style="western"><surname>Tice</surname><given-names>RR</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>EL</given-names></name></person-group><article-title>A simple technique for quantitation of low levels of DNA damage in individual cells</article-title><source>Exp Cell Res</source><year>1988</year><volume>175</volume><issue>1</issue><fpage>184</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/0014-4827(88)90265-0</pub-id><pub-id pub-id-type="pmid">3345800</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988;175(1):184&#8211;91. 10.1016/0014-4827(88)90265-0.<pub-id pub-id-type="pmid">3345800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0014-4827(88)90265-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azqueta</surname><given-names>A</given-names></name><name name-style="western"><surname>Collins</surname><given-names>AR</given-names></name></person-group><article-title>The essential comet assay: a comprehensive guide to measuring DNA damage and repair</article-title><source>Arch Toxicol</source><year>2013</year><volume>87</volume><issue>6</issue><fpage>949</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1007/s00204-013-1070-0</pub-id><pub-id pub-id-type="pmid">23685795</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Azqueta A, Collins AR. The essential comet assay: a comprehensive guide to measuring DNA damage and repair. Arch Toxicol. 2013;87(6):949&#8211;68. 10.1007/s00204-013-1070-0.<pub-id pub-id-type="pmid">23685795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00204-013-1070-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fenech</surname><given-names>M</given-names></name></person-group><article-title>Cytokinesis-block micronucleus cytome assay</article-title><source>Nat Protoc</source><year>2007</year><volume>2</volume><issue>5</issue><fpage>1084</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.77</pub-id><pub-id pub-id-type="pmid">17546000</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Fenech M. Cytokinesis-block micronucleus cytome assay. Nat Protoc. 2007;2(5):1084&#8211;104. 10.1038/nprot.2007.77.<pub-id pub-id-type="pmid">17546000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nprot.2007.77</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norppa</surname><given-names>H</given-names></name><name name-style="western"><surname>Falck</surname><given-names>GC</given-names></name></person-group><article-title>What do human micronuclei contain?</article-title><source>Mutagenesis</source><year>2003</year><volume>18</volume><issue>3</issue><fpage>221</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1093/mutage/18.3.221</pub-id><pub-id pub-id-type="pmid">12714687</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Norppa H, Falck GC. What do human micronuclei contain? Mutagenesis. 2003;18(3):221&#8211;33. 10.1093/mutage/18.3.221.<pub-id pub-id-type="pmid">12714687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/mutage/18.3.221</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pearce</surname><given-names>EJ</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>AS</given-names></name></person-group><article-title>The immunobiology of schistosomiasis</article-title><source>Nat Rev Immunol</source><year>2002</year><volume>2</volume><issue>7</issue><fpage>499</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1038/nri843</pub-id><pub-id pub-id-type="pmid">12094224</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Pearce EJ, MacDonald AS. The immunobiology of schistosomiasis. Nat Rev Immunol. 2002;2(7):499&#8211;511. 10.1038/nri843.<pub-id pub-id-type="pmid">12094224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri843</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fairfax</surname><given-names>K</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>M</given-names></name><name name-style="western"><surname>Huang</surname><given-names>SC</given-names></name><name name-style="western"><surname>Everts</surname><given-names>B</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>EJ</given-names></name></person-group><article-title>Th2 responses in schistosomiasis</article-title><source>Semin Immunopathol</source><year>2012</year><volume>34</volume><issue>6</issue><fpage>863</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1007/s00281-012-0346-2</pub-id><pub-id pub-id-type="pmid">23139101</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Fairfax K, Nascimento M, Huang SC, Everts B, Pearce EJ. Th2 responses in schistosomiasis. Semin Immunopathol. 2012;34(6):863&#8211;71. 10.1007/s00281-012-0346-2. PMID: 23139101.<pub-id pub-id-type="pmid">23139101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00281-012-0354-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finkelman</surname><given-names>FD</given-names></name><name name-style="western"><surname>Shea-Donohue</surname><given-names>T</given-names></name><name name-style="western"><surname>Morris</surname><given-names>SC</given-names></name><name name-style="western"><surname>Gildea</surname><given-names>L</given-names></name><name name-style="western"><surname>Strait</surname><given-names>R</given-names></name><name name-style="western"><surname>Madden</surname><given-names>KB</given-names></name><name name-style="western"><surname>Schopf</surname><given-names>L</given-names></name><name name-style="western"><surname>Urban</surname><given-names>JF Jr.</given-names></name></person-group><article-title>Interleukin-4- and interleukin-13-mediated host protection against intestinal nematode parasites</article-title><source>Immunol Rev</source><year>2004</year><volume>201</volume><issue>1</issue><fpage>139</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1111/j.0105-2896.2004.00192.x</pub-id><pub-id pub-id-type="pmid">15361238</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Finkelman FD, Shea-Donohue T, Morris SC, Gildea L, Strait R, Madden KB, Schopf L, Urban JF Jr. Interleukin-4- and interleukin-13-mediated host protection against intestinal nematode parasites. Immunol Rev. 2004;201(1):139&#8211;55. 10.1111/j.0105-2896.2004.00192.x.<pub-id pub-id-type="pmid">15361238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.0105-2896.2004.00192.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wynn</surname><given-names>TA</given-names></name><name name-style="western"><surname>Cheever</surname><given-names>AW</given-names></name><name name-style="western"><surname>Jankovic</surname><given-names>D</given-names></name><name name-style="western"><surname>Poindexter</surname><given-names>RW</given-names></name><name name-style="western"><surname>Caspar</surname><given-names>P</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>FA</given-names></name><name name-style="western"><surname>Sher</surname><given-names>A</given-names></name></person-group><article-title>An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection</article-title><source>Nature</source><year>1995</year><volume>377</volume><issue>6549</issue><fpage>531</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1038/377531a0</pub-id><pub-id pub-id-type="pmid">7637808</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Wynn TA, Cheever AW, Jankovic D, Poindexter RW, Caspar P, Lewis FA, Sher A. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature. 1995;377(6549):531&#8211;4. 10.1038/377531a0. PMID: 7566151.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/376594a0</pub-id><pub-id pub-id-type="pmid">7637808</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gause</surname><given-names>WC</given-names></name><name name-style="western"><surname>Wynn</surname><given-names>TA</given-names></name><name name-style="western"><surname>Allen</surname><given-names>JE</given-names></name></person-group><article-title>Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths</article-title><source>Nat Rev Immunol</source><year>2013</year><volume>13</volume><issue>8</issue><fpage>607</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/nri3476</pub-id><pub-id pub-id-type="pmid">23827958</pub-id><pub-id pub-id-type="pmcid">PMC3789590</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Gause WC, Wynn TA, Allen JE. Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol. 2013;13(8):607&#8211;14. 10.1038/nri3476.<pub-id pub-id-type="pmid">23827958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3476</pub-id><pub-id pub-id-type="pmcid">PMC3789590</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitre</surname><given-names>E</given-names></name><name name-style="western"><surname>Nutman</surname><given-names>TB</given-names></name></person-group><article-title>IgE memory: persistence of antigen-specific IgE responses years after treatment of human filarial infections</article-title><source>J Allergy Clin Immunol</source><year>2006</year><volume>118</volume><issue>2</issue><fpage>401</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2006.05.008</pub-id><pub-id pub-id-type="pmid">16630955</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Mitre E, Nutman TB. IgE memory: persistence of antigen-specific IgE responses years after treatment of human filarial infections. J Allergy Clin Immunol. 2006;118(2):401&#8211;9. 10.1016/j.jaci.2006.05.008. PMID: 16890765.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2005.12.1341</pub-id><pub-id pub-id-type="pmid">16630955</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frank</surname><given-names>MM</given-names></name></person-group><article-title>Complement in the pathophysiology of human disease</article-title><source>N Engl J Med</source><year>1987</year><volume>317</volume><issue>27</issue><fpage>1525</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1056/NEJM198712313172706</pub-id><pub-id pub-id-type="pmid">3295544</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Frank MM. Complement in the pathophysiology of human disease. N Engl J Med. 1987;317(27):1525&#8211;30. 10.1056/NEJM198712313172706. PMID: 3317054.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM198706113162407</pub-id><pub-id pub-id-type="pmid">3295544</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>MS</given-names></name><name name-style="western"><surname>Mentink-Kane</surname><given-names>MM</given-names></name><name name-style="western"><surname>Pesce</surname><given-names>JT</given-names></name><name name-style="western"><surname>Ramalingam</surname><given-names>TR</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>R</given-names></name><name name-style="western"><surname>Wynn</surname><given-names>TA</given-names></name></person-group><article-title>Immunopathology of schistosomiasis</article-title><source>Immunol Cell Biol</source><year>2007</year><volume>85</volume><issue>8</issue><fpage>680</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/sj.icb.7100118</pub-id><pub-id pub-id-type="pmcid">PMC3437548</pub-id><pub-id pub-id-type="pmid">17160074</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Wilson MS, Mentink-Kane MM, Pesce JT, Ramalingam TR, Thompson R, Wynn TA. Immunopathology of schistosomiasis. Immunol Cell Biol. 2007;85(8):680&#8211;6. 10.1038/sj.icb.7100118. PMID: 17592492.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.icb.7100014</pub-id><pub-id pub-id-type="pmcid">PMC3437548</pub-id><pub-id pub-id-type="pmid">17160074</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonassi</surname><given-names>S</given-names></name><name name-style="western"><surname>Norppa</surname><given-names>H</given-names></name><name name-style="western"><surname>Ceppi</surname><given-names>M</given-names></name><name name-style="western"><surname>Str&#246;mberg</surname><given-names>U</given-names></name><name name-style="western"><surname>Vermeulen</surname><given-names>R</given-names></name><name name-style="western"><surname>Znaor</surname><given-names>A</given-names></name><name name-style="western"><surname>Cebulska-Wasilewska</surname><given-names>A</given-names></name><name name-style="western"><surname>Fabianova</surname><given-names>E</given-names></name><name name-style="western"><surname>Fucic</surname><given-names>A</given-names></name><name name-style="western"><surname>Gundy</surname><given-names>S</given-names></name><name name-style="western"><surname>Hansteen</surname><given-names>IL</given-names></name><name name-style="western"><surname>Knudsen</surname><given-names>LE</given-names></name><name name-style="western"><surname>Lazutka</surname><given-names>J</given-names></name><name name-style="western"><surname>Rossner</surname><given-names>P</given-names></name><name name-style="western"><surname>Sram</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Boffetta</surname><given-names>P</given-names></name></person-group><article-title>Chromosomal aberration frequency in lymphocytes predicts the risk of cancer: results from a pooled cohort study of 22 358 subjects in 11 countries</article-title><source>Carcinogenesis</source><year>2008</year><volume>29</volume><issue>6</issue><fpage>1178</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgn075</pub-id><pub-id pub-id-type="pmid">18356148</pub-id><pub-id pub-id-type="pmcid">PMC2443275</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Bonassi S, Norppa H, Ceppi M, Str&#246;mberg U, Vermeulen R, Znaor A, Cebulska-Wasilewska A, Fabianova E, Fucic A, Gundy S, Hansteen IL, Knudsen LE, Lazutka J, Rossner P, Sram RJ, Boffetta P. Chromosomal aberration frequency in lymphocytes predicts the risk of cancer: results from a pooled cohort study of 22 358 subjects in 11 countries. Carcinogenesis. 2008;29(6):1178&#8211;83. 10.1093/carcin/bgn075.<pub-id pub-id-type="pmid">18356148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/carcin/bgn075</pub-id><pub-id pub-id-type="pmcid">PMC2443275</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van der Werf</surname><given-names>MJ</given-names></name><name name-style="western"><surname>de Vlas</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Brooker</surname><given-names>S</given-names></name><name name-style="western"><surname>Looman</surname><given-names>CW</given-names></name><name name-style="western"><surname>Nagelkerke</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Habbema</surname><given-names>JD</given-names></name><name name-style="western"><surname>Engels</surname><given-names>D</given-names></name></person-group><article-title>Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa</article-title><source>Acta Trop</source><year>2003</year><volume>86</volume><issue>2-3</issue><fpage>125</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/s0001-706x(03)00029-9</pub-id><pub-id pub-id-type="pmid">12745133</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop. 2003;86(2&#8211;3):125&#8211;39. 10.1016/s0001-706x(03)00029-9. PMID: 12745133.<pub-id pub-id-type="pmid">12745133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0001-706x(03)00029-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badawi</surname><given-names>AF</given-names></name><name name-style="western"><surname>Mostafa</surname><given-names>MH</given-names></name><name name-style="western"><surname>Probert</surname><given-names>A</given-names></name><name name-style="western"><surname>O'Connor</surname><given-names>PJ</given-names></name></person-group><article-title>Role of schistosomiasis in human bladder cancer: evidence of association, aetiological factors, and basic mechanisms of carcinogenesis</article-title><source>Eur J Cancer Prev</source><year>1995</year><volume>4</volume><issue>1</issue><fpage>45</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1097/00008469-199502000-00006</pub-id><pub-id pub-id-type="pmid">7728097</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Badawi AF, Mostafa MH, Probert A, O&#8217;Connor PJ. Role of schistosomiasis in human bladder cancer: evidence of association, aetiological factors, and basic mechanisms of carcinogenesis. Eur J Cancer Prev. 1995;4(1):45&#8211;59. 10.1097/00008469-199502000-00006. PMID: 7537139.<pub-id pub-id-type="pmid">7728097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00008469-199502000-00004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><collab>International Agency for Research on Cancer</collab></person-group><article-title>Schistosomes, liver flukes and Helicobacter pylori. IARC working group on the evaluation of carcinogenic risks to humans. Lyon, 7&#8211;14 June 1994</article-title><source>IARC Monogr Eval Carcinog Risks Hum</source><year>1994</year><volume>61</volume><fpage>1</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">7715068</pub-id><pub-id pub-id-type="pmcid">PMC7681621</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC working group on the evaluation of carcinogenic risks to humans. Lyon, 7&#8211;14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1&#8211;241. PMID: 7715068.<pub-id pub-id-type="pmid">7715068</pub-id><pub-id pub-id-type="pmcid">PMC7681621</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>GF</given-names></name><name name-style="western"><surname>Cruise</surname><given-names>KM</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>CB</given-names></name><name name-style="western"><surname>Anders</surname><given-names>RF</given-names></name></person-group><article-title>Schistosome antigens on the surface and excretory-secretory products of developing schistosomula of Schistosoma japonicum</article-title><source>Int J Parasitol</source><year>1981</year><volume>11</volume><issue>1</issue><fpage>63</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/0020-7519(81)90029-0</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Mitchell GF, Cruise KM, Chapman CB, Anders RF. Schistosome antigens on the surface and excretory-secretory products of developing schistosomula of Schistosoma japonicum. Int J Parasitol. 1981;11(1):63&#8211;75. 10.1016/0020-7519(81)90029-0. PMID: 7228485.</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooke</surname><given-names>MS</given-names></name><name name-style="western"><surname>Evans</surname><given-names>MD</given-names></name><name name-style="western"><surname>Dizdaroglu</surname><given-names>M</given-names></name><name name-style="western"><surname>Lunec</surname><given-names>J</given-names></name></person-group><article-title>Oxidative. DNA damage: mechanisms, mutation, and disease</article-title><source>FASEB J</source><year>2003</year><volume>17</volume><issue>10</issue><fpage>1195</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1096/fj.02-0752rev</pub-id><pub-id pub-id-type="pmid">12832285</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative. DNA damage: mechanisms, mutation, and disease. FASEB J. 2003;17(10):1195&#8211;214. 10.1096/fj.02-0752rev.<pub-id pub-id-type="pmid">12832285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.02-0752rev</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McManus</surname><given-names>DP</given-names></name><name name-style="western"><surname>Dunne</surname><given-names>DW</given-names></name><name name-style="western"><surname>Sacko</surname><given-names>M</given-names></name><name name-style="western"><surname>Utzinger</surname><given-names>J</given-names></name><name name-style="western"><surname>Vennervald</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>XN</given-names></name><name name-style="western"><surname>Schistosomiasis</surname></name></person-group><article-title>Schistosomiasis</article-title><source>Nat Rev Dis Primers</source><year>2018</year><volume>4</volume><issue>1</issue><fpage>31</fpage><pub-id pub-id-type="doi">10.1038/s41572-018-0013-8</pub-id><pub-id pub-id-type="pmid">30093684</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou XN, Schistosomiasis. Schistosomiasis. Nat Rev Dis Primers. 2018;4(1):31. 10.1038/s41572-018-0013-8. PMID: 30093684.<pub-id pub-id-type="pmid">30093684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-018-0013-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honeycutt</surname><given-names>J</given-names></name><name name-style="western"><surname>Hammam</surname><given-names>O</given-names></name><name name-style="western"><surname>Fu</surname><given-names>CL</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>MH</given-names></name></person-group><article-title>Controversies and challenges in research on urogenital schistosomiasis-associated bladder cancer</article-title><source>Trends Parasitol</source><year>2014</year><volume>30</volume><issue>7</issue><fpage>324</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2014.05.004</pub-id><pub-id pub-id-type="pmid">24913983</pub-id><pub-id pub-id-type="pmcid">PMC4085545</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Honeycutt J, Hammam O, Fu CL, Hsieh MH. Controversies and challenges in research on urogenital schistosomiasis-associated bladder cancer. Trends Parasitol. 2014;30(7):324&#8211;32. 10.1016/j.pt.2014.05.004.<pub-id pub-id-type="pmid">24913983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pt.2014.05.004</pub-id><pub-id pub-id-type="pmcid">PMC4085545</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Bolkainy</surname><given-names>MN</given-names></name><name name-style="western"><surname>Mokhtar</surname><given-names>NM</given-names></name><name name-style="western"><surname>Ghoneim</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hussein</surname><given-names>MH</given-names></name></person-group><article-title>The impact of schistosomiasis on the pathology of bladder carcinoma</article-title><source>Cancer</source><year>1981</year><volume>48</volume><issue>11</issue><fpage>2643</fpage><lpage>8</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(19811201)48:11&amp;#x0003c;2643::aid-cncr2820481141&amp;#x0003e;3.0.co;2-k</pub-id><pub-id pub-id-type="pmid">7306921</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">El-Bolkainy MN, Mokhtar NM, Ghoneim MA, Hussein MH. The impact of schistosomiasis on the pathology of bladder carcinoma. Cancer. 1981;48(11):2643&#8211;8. 10.1002/1097-0142(19811201)48:11%3C;2643::aid-cncr2820481141%3E;3.0.co;2-k. PMID: 7306925.<pub-id pub-id-type="pmid">7306921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(19811215)48:12&lt;2643::aid-cncr2820481216&gt;3.0.co;2-c</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>